Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$5.94
+0.16 (+2.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-102.4M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.7%
↓Gross Margin
46.0%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.6%
FCF CAGR
—
FCF margin
-10.6%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $462.8M · net income $-238.7M · FCF $-49.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $462.8M | $462.8M | $484.0M | $645.0M | $549.5M |
| Net Income | $-238.7M | $-238.7M | $-123.4M | $25.4M | $44.8M |
| EBITDA | $-161.3M | $-161.3M | $-36.3M | $108.7M | $121.5M |
| EPS | -0.64 | -0.64 | -0.33 | 0.07 | 0.14 |
| Gross Margin | 46.0% | 46.0% | 49.1% | 56.0% | 58.5% |
| Operating Margin | -1.3% | -1.3% | -10.8% | 3.1% | 8.6% |
| Net Margin | -51.6% | -51.6% | -25.5% | 3.9% | 8.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.16 | 0.10 | 0.02 |
| Current Ratio | 0.89 | 0.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-49.2M | $-49.2M | $-102.4M | $-178.3M | $-33.0M |
| Returns | |||||
| ROE | -17.7% | -17.7% | -7.8% | 1.5% | 2.6% |
| Valuation | |||||
| P/E | — | — | — | 173.14 | 59.21 |
| EV/EBITDA | — | — | — | 38.81 | 17.82 |
| P/B | 1.64 | 1.64 | 1.51 | 2.56 | 1.55 |
| Growth & Yield | |||||
| Revenue Growth | -4.4% | -4.4% | -25.0% | 17.4% | — |
| EPS Growth | -93.9% | -93.9% | -571.4% | -50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.33 → -0.64
Residual
-20.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.